Grace Therapeutics opened lower at $1.84, compared with its previous close of $1.86. In the last trading session, the stock traded between $1.82 and $1.88. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Grace Therapeutics is now worth
$ 56.73
Resulting in a loss of
$ 43.27 (43.27%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-1.83%)
Day High
$1.88
Day Low
$1.82
Day Open
$1.84
Prev Close
$1.86
Volume
72,789
1W Return
0.61%
1M Return
-9.40%
3M Return
-13.16%
6M Return
-22.51%
1Y Return
-39.32%
Fundamentals
Market Cap ($ Mn)
38
PE Ratio
-
PB Ratio
0.72
PEG Ratio
-
ROE
-16.16%
ROCE
-20.38%
EPS (TTM)
$-0.97
Investment Returns
1 Week
0.61%
1 Month
-9.40%
3 Months
-13.16%
6 Months
-22.51%
9 Months
-49.28%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
25Aug
Grace Therapeutics files prospectus for 4.762m share sale
Grace Therapeutics Inc. filed a Form S-3 with the SEC. The offering includes 4.762 million common shares. Shares are being sold by existing shareholders. No proceeds will go to the company. Filing is available via the SEC EDGAR system.
Grace Therapeutics reported a Q1 EPS of $(0.91), missing the $(0.18) estimate by 405.56%. This signifies a 333.33% widening of losses compared to the $(0.21) EPS from the prior year period.
3mo ago
28Jul
Grace Therapeutics clears FDA safety hurdles for GTx-104
Grace Therapeutics confirmed no clinical safety issues for GTx-104 after receiving FDA meeting minutes. The CRL cited only cGMP manufacturing issues, prompting a dual-source production strategy to ensure NDA resubmission.
3mo ago
18Jun
Grace Therapeutics narrows FY26 net loss to $7.8 million
Grace Therapeutics narrowed its fiscal year 2026 net loss to $7.8 million, driven by lower R&D expenses following the close-out of a Phase 3 trial. The company reported Q4 EPS of $(0.06), beating analyst estimates, while maintaining $17.0 million in cash to fund operations.
4mo ago
8Jun
Schall Law investigates Grace Therapeutics after FDA rejection
The Schall Law Firm has launched an investigation into Grace Therapeutics concerning potential securities law violations. The probe follows a 45.5% drop in share price after the FDA issued a Complete Response Letter for the company's GTx-104 drug application, citing manufacturing and toxicology issues.
